Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Autoimmunity

• Publication date

  1998-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1006/JAUT.1998.0205PMID 9776710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection.

  1995cited by this paper
• Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120

  1995cited by this paper
• Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.

  1994cited by this paper
• Sensorimotor neuropathy resembling CIDP in patients receiving FK506

  1994cited by this paper
• A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

  1994cited by this paper
• Cyclosporin A and FK506 inhibit activation-induced cell death in the murine WEHI-231 B cell line.

  1994cited by this paper
• Apoptotic elimination of Vβ8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vβ8.2+ encephalitogenic T cells

  1994cited by this paper
• The Mechanism of Action of FK‐506 and Cyclosporin A

  1993cited by this paper
• Immunopharmacologic Modulation of Experimental Allergic Encephalomyelitis: Low‐Dose Cyclosporin‐A Treatment Causes Disease Relapse and Increased Systemic T and B Cell‐Mediated Myelin‐Directed Autoimmunity

  1993cited by this paper
• Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas

  1992cited by this paper
• Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets.

  1992cited by this paper
• Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A.

  1991cited by this paper
• The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone.

  1991cited by this paper
• Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro.

  1991cited by this paper
• Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A.

  1991cited by this paper
• Effects of FK 506 on acute experimental allergic encephalomyelitis.

  1991cited by this paper
• Preventive and therapeutic effects of cyclosporin and valine2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.

  1988cited by this paper
• Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats.

  1988cited by this paper
• Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat.

  1988cited by this paper
• Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide.

  1987cited by this paper
• Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.

  1979cited by this paper
• Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats.

  1969cited by this paper

• The impact of tacrolimus on the immunopathogenesis of staphylococcal enterotoxin-induced systemic inflammatory response syndrome and pneumonia.

  2012cites this paper
• Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis.

  2005cites this paper
• Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus.

  2000cites this paper
• Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/Tacrolimus

  2000cites this paper